AI Personalized Medicine

Medicine today is designed for the average patient, not you. The same drug, same dose, same treatment protocol — regardless of your genetics, microbiome, lifestyle, or the 10,000 data points your wearable collects daily. This one-size-fits-all approach means 40% of patients receive drugs that don't work for them, costing the US healthcare system $528 billion annually in ineffective treatments.

Whole genome sequencing dropped from $100M in 2001 to under $200 in 2025. Wearable health data (continuous glucose monitors, heart rate variability, sleep tracking) generates millions of daily data points per person. EHR systems are finally interoperable via FHIR APIs. For the first time, we have enough data per patient to make personalization work — and AI models sophisticated enough to find the patterns.

The precision medicine market is projected to reach $175 billion by 2028. Pharmacogenomics alone — matching drugs to genetic profiles — is a $15B opportunity. Companies like Tempus ($6B valuation) proved the model in oncology, but most disease areas remain untouched. The consumer genomics market (23andMe, etc.) created 40 million genotyped consumers hungry for actionable health insights.

Founders who combine clinical understanding with ML expertise. You need someone who can navigate FDA pathways and understand clinical validation requirements. The ideal team has a physician or clinical researcher paired with a data scientist experienced in health data. Prior experience with HIPAA compliance and health data infrastructure is crucial — this is a regulated space where trust is everything.

Ankit Gupta emphasizes the cost curve: genome sequencing costs are falling faster than Moore's Law. This creates a window where startups can build what was impossible two years ago. The vision is an AI system that ingests your genome, medical history, wearable data, and lab results to recommend the optimal treatment — not the average treatment — for your specific biology.